Early diagnosis of sepsis-related hepatic dysfunction and its prognostic impact on survival: a prospective study with the LiMAx test

Not Applicable

• Conditions: A41; K72; Other sepsis; Hepatic failure, not elsewhere classified

• Registration Number: DRKS00003085
• Lead Sponsor: Charitè - Universitätsmedizin Berlin - Campus VirchowKlinik für Allgemein-, Viszeral- und Transplantationschirurgie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-09-02
• Study Completion: 2013-03-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

Bacterial Sepsis
Inform consent present

Exclusion Criteria

Allergy against ICG or Methacetin
Chemotherapy in the last 8 weeks
Immunosuppression (Equivalent of Cortison >5mg)
Advanced liver dysfunction prior to actual disease
Any organ transplantation
HIV
Pregnancy, breast feeding
Absent inform consent
Factors, limitating the ability of patients to cooperate during study (e. g. reduced mental function, drug abuse)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlation between result of the Maximal Liver Function Capacity Test (LiMAx-Test) the mortality rate

Secondary Outcome Measures

Name	Time	Method
Comparison of the result of the Maximal Liver Function Capacity Test (LiMAx-Test) with the Indocyaningreen plasmadilution rate and other parameter for assessment of the liver function (transaminases, bilirubine, coagulation-tests, zxtokines)<br>Length of stay in intensive care unit<br>Lenght of stay in hospital